A Phase 2 interventional study of MAA868 Cohort 1 and MAA868 Cohort 2 in Atrial Fibrillation, sponsored by Anthos Therapeutics, Inc.. Completed at 6 sites in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2022-01-11.
Sponsored by Anthos Therapeutics, Inc. · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 993 studies in Atrial Fibrillation with a site in United States — 161 open to participants now, 220 under way, 15 of them phase 3. Atrial Fibrillation · United States.
Among the 993 studies in Atrial Fibrillation with a site in United States, this one is the 541st largest by enrollment of the 679 interventional ones that give a count, is one of 58 that started in 2019, is one of 55 in phase 2, and was the 642nd registered.
4,011 studies on the registry are indexed under Atrial Fibrillation; 961 are open to participants now.
Browse Atrial Fibrillation studies →161 of the 993 studies in Atrial Fibrillation with a site in United States are open now. Recruiting first, the newest first:
Kardium Inc. · Sites in United States
Ages 18+
Boston Scientific Corporation · Sites in United States
Ages 18+
Bayer · Sites in United States, Belgium, Bulgaria and 5 more countries
Ages 18–85
Texas Cardiac Arrhythmia Research Foundation · Sites in United States
Ages 18+
Oslo University Hospital · Sites in United States, Belgium, France and 7 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
993 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 30 · Phase 2 71 · Phase 3 107 · Phase 4 87
First in 1989; this study’s year is marked. 58 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 28 is below the median of 150 across 2,477 interventional studies indexed under Atrial Fibrillation.
Median enrollment 127 across the 679 interventional studies, 200 across the 308 observational. Of the 675 that completed or were terminated, 304 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
349 of 993 have an industry lead sponsor. The 10 most frequent:
Anthos Therapeutics, Inc. is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
Anthos Therapeutics, Inc. has 4 studies filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
76 of the studies in Atrial Fibrillation with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06376916Phase 3Wake Forest University Health SciencesComparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR | 2026-12 |
| NCT05757869Phase 3Janssen Research & Development, LLCA Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation | 2026-12-08 |
| NCT03907046Phase 3Yale UniversityAnticoagulation in ICH Survivors for Stroke Prevention and Recovery | 2027-04 |
| NCT05174052Phase 3University of OklahomaDapagliflozin in Patients With Atrial Fibrillation (DAPA-AF) | 2027-04 |
| NCT02750319Phase 3Memorial Sloan Kettering Cancer CenterAmiodarone and N-Acetylcysteine or Amiodarone Alone for Preventing Atrial Fibrillation After Thoracic Surgery | 2027-04 |
Add all 76 to your calendar (.ics) → With an account.
Among the 993 studies in Atrial Fibrillation with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a multicenter, randomized, subject and Investigator-blinded, placebo-controlled, parallel-group, multiple ascending dose-ranging study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) effects of MAA868 in patients with atrial fibrillation (AF) or flutter at low risk of thromboembolic stroke or peripheral embolism.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol defined Inclusion/Exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subcutaneous injection on Day 1 with two subsequent monthly injections
Biological: MAA868 Cohort 1 · Biological: MAA868 Cohort 2 · Biological: MAA868 Cohort 3
Subcutaneous injection: Placebo on Day 1 with two subsequent monthly injections
Other: Placebo
Subcutaneous injection: low dose
Subcutaneous injection: high dose
Subcutaneous injection: Dose to be determined.
Subcutaneous injection: Placebo
Number of Participants That Achieved More Than or Equal to 50%, 80%, and 90% Factor XI Inhibition at Trough After the Third Dose (Day 91) at Different Dose Levels of MAA868
Number of participants achieving more than or equal to 50%, 80%, and 90% inhibition of factor XI (less than 50%, 20%, or 10% free factor XI) at trough after the third dose on Day 91 at different dose levels of MAA868
Time frame: Day 91
Number of Participants Achieving More Than or Equal to 50%, 80%, and 90% Factor XI Inhibition at Trough After First (Day 31) and Second Doses (Day 61) at Different Dose Levels of MAA868
Number of participants achieving more than or equal to 50%, 80%, and 90% inhibition of factor XI (less than 50%, 20%, or 10% free factor XI) at trough on Day 31 (after first dose) and Day 61 (after second dose) at different dose levels of MAA868
Time frame: Day 31 and Day 61
Overall Number of Participants Who Experienced Adverse Events, Including Serious Adverse Events, During the Treatment Period and Through End of Study
Overall number of participants who experienced adverse events following multiple subcutaneous administration of MAA868 compared to placebo in participants with atrial fibrillation or atrial flutter
Time frame: Day 1 through end of study, up to 170 days
Incidence of Major Bleeding Events, Clinically Relevant Non-major Bleeding Events and Total Bleeding With MAA868 Relative to Placebo
Occurrence of confirmed major bleeding events, clinically relevant non-major bleeding events and total bleeding events during the treatment period
Time frame: Day 1 through end of study, up to 170 days
Immunogenicity of MAA868
Number of participants with anti-drug (MAA868) antibodies for all participants who received MAA868 120 mg or MAA868 180 mg. "Non-evaluable observation" refers to participants who had no sample collected (due to no visit or remote visit) or for whom the sample was not frozen.
Time frame: Days 1, 31, 61, 71, 91, 121 and 170
No subjects were enrolled in the optional Cohort 3.
| Milestone | Placebo | MAA868 120 mg | MAA868 180 mg |
|---|---|---|---|
| Started | 5 | 6 | 7 |
| Completed | 5 | 6 | 6 |
| Not completed | 0 | 0 | 1 |
| Withdrew: Physician decision | 0 | 0 | 1 |
Number of participants achieving more than or equal to 50%, 80%, and 90% inhibition of factor XI (less than 50%, 20%, or 10% free factor XI) at trough after the third dose on Day 91 at different dose levels of MAA868
| Participants | Placebo | MAA868 120 mg | MAA868 180 mg |
|---|---|---|---|
| More than or equal to 50% inhibition of factor XI | 0 | 2 | 4 |
| More than or equal to 80% inhibition of factor XI | 0 | 0 | 1 |
| More than or equal to 90% inhibition of factor XI | 0 | 0 | 0 |
Number of participants achieving more than or equal to 50%, 80%, and 90% inhibition of factor XI (less than 50%, 20%, or 10% free factor XI) at trough on Day 31 (after first dose) and Day 61 (after second dose) at different dose levels of MAA868
| Participants | Placebo | MAA868 120 mg | MAA868 180 mg |
|---|---|---|---|
| More than or equal to 50% factor XI inhibition : Day 31 | 0 | 1 | 5 |
| More than or equal to 50% factor XI inhibition : Day 61 | 0 | 2 | 5 |
| More than or equal to 80% factor XI inhibition : Day 31 | 0 | 1 | 3 |
| More than or equal to 80% factor XI inhibition : Day 61 | 0 | 0 | 1 |
| More than or equal to 90% factor XI inhibition : Day 31 | 0 | 0 | 0 |
| More than or equal to 90% factor XI inhibition : Day 61 | 0 | 0 | 0 |
Overall number of participants who experienced adverse events following multiple subcutaneous administration of MAA868 compared to placebo in participants with atrial fibrillation or atrial flutter
| Participants | Placebo | MAA868 120 mg | MAA868 180 mg |
|---|---|---|---|
| Overall Number of Participants Who Experienced Adverse Events, Including Serious Adverse Events, During the Treatment Period and Through End of Study | 4 | 5 | 3 |
Occurrence of confirmed major bleeding events, clinically relevant non-major bleeding events and total bleeding events during the treatment period
| incidence of events | Placebo | MAA868 120 mg | MAA868 180 mg |
|---|---|---|---|
| Major bleeding events | 0 | 0 | 0 |
| Clinically relevant non-major bleeding events | 0 | 0 | 0 |
| Nuisance (not clinically relevant) bleeding events | 2 | 1 | 1 |
| No bleeding events | 0 | 1 | 0 |
Number of participants with anti-drug (MAA868) antibodies for all participants who received MAA868 120 mg or MAA868 180 mg. "Non-evaluable observation" refers to participants who had no sample collected (due to no visit or remote visit) or for whom the sample was not frozen.
| Participants | MAA868 120 mg | MAA868 180 mg |
|---|---|---|
| Baseline — Negative | 6 | 7 |
| Baseline — Positive | 0 | 0 |
| Baseline — Non-evaluable observation | 0 | 0 |
| Day 1 — Negative | 6 | 7 |
| Day 1 — Positive | 0 | 0 |
| Day 1 — Non-evaluable observation | 0 | 0 |
| Day 31 — Negative | 6 | 7 |
| Day 31 — Positive | 0 | 0 |
| Day 31 — Non-evaluable observation | 0 | 0 |
| Day 61 — Negative | 3 | 6 |
| Day 61 — Positive | 0 | 0 |
| Day 61 — Non-evaluable observation | 3 | 1 |
| Day 71 — Negative | 4 | 6 |
| Day 71 — Positive | 0 | 0 |
| Day 71 — Non-evaluable observation | 2 | 1 |
| Day 91 — Negative | 5 | 5 |
| Day 91 — Positive | 0 | 0 |
| Day 91 — Non-evaluable observation | 1 | 2 |
| Day 121 — Negative | 5 | 5 |
| Day 121 — Positive | 0 | 0 |
| Day 121 — Non-evaluable observation | 1 | 2 |
| Day 170 — Negative | 6 | 7 |
| Day 170 — Positive | 0 | 0 |
| Day 170 — Non-evaluable observation | 0 | 0 |
Collected over Adverse event information was collected at every study visit from providing written informed consent for participation in the study (on Days -28 to -3) until Day 170 (the end of study visit).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/5 (0%) | 0/5 (0%) | 4/5 (80%) |
| MAA868 120 mg | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| MAA868 180 mg | 0/7 (0%) | 0/7 (0%) | 3/7 (42.9%) |
| Event | Placebo | MAA868 120 mg | MAA868 180 mg |
|---|---|---|---|
| Back painMusculoskeletal and connective tissue disorders | 1/5 | 0/6 | 1/7 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 1/5 | 0/6 | 0/7 |
| DiarrhoeaGastrointestinal disorders | 1/5 | 1/6 | 0/7 |
| Blood pressure increasedInvestigations | 1/5 | 0/6 | 0/7 |
| Eosinophil count increasedInvestigations | 1/5 | 0/6 | 0/7 |
| Renal impairmentRenal and urinary disorders | 1/5 | 0/6 | 0/7 |
| ContusionInjury, poisoning and procedural complications | 1/5 | 0/6 | 0/7 |
| HaematomaVascular disorders | 1/5 | 0/6 | 0/7 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/5 | 1/6 | 0/7 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/5 | 1/6 | 0/7 |
| Age, Continuous(years) | Placebo | MAA868 120 mg | MAA868 180 mg | Total |
|---|---|---|---|---|
| Mean | 52.2 ± 18.79 | 53.8 ± 9.24 | 58.1 ± 8.34 | 55.1 ± 11.81 |
| Age, Customized(years) | Placebo | MAA868 120 mg | MAA868 180 mg | Total |
|---|---|---|---|---|
| 18 to 20 | 1 | 0 | 0 | 1 |
| 21 to 30 | 0 | 0 | 0 | 0 |
| 31 to 40 | 0 | 1 | 0 | 1 |
| 41 to 50 | 0 | 0 | 1 | 1 |
| 51 to 60 | 2 | 4 | 4 | 10 |
| 61 to 70 | 2 | 1 | 2 | 5 |
| 71 to 80 | 0 | 0 | 0 | 0 |
| 81 to 85 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Placebo | MAA868 120 mg | MAA868 180 mg | Total |
|---|---|---|---|---|
| Female | 0 | 3 | 2 | 5 |
| Male | 5 | 3 | 5 | 13 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | MAA868 120 mg | MAA868 180 mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 5 | 6 | 7 | 18 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | MAA868 120 mg | MAA868 180 mg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 2 | 2 |
| White | 5 | 6 | 5 | 16 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Height(centimeters) | Placebo | MAA868 120 mg | MAA868 180 mg | Total |
|---|---|---|---|---|
| Mean | 182.01 ± 5.573 | 174.60 ± 11.311 | 175.74 ± 8.337 | 177.10 ± 8.918 |
| Weight(kg) | Placebo | MAA868 120 mg | MAA868 180 mg | Total |
|---|---|---|---|---|
| Mean | 99.352 ± 13.1715 | 91.667 ± 7.1102 | 94.933 ± 23.2745 | 95.072 ± 16.0115 |
| Body mass index(kg/m^2) | Placebo | MAA868 120 mg | MAA868 180 mg | Total |
|---|---|---|---|---|
| Mean | 30.022 ± 4.1647 | 30.392 ± 4.7558 | 30.887 ± 8.6754 | 30.482 ± 6.1179 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2019 to primary completion in Dec 2020, 12 months.
Results were first posted in Dec 2021, 11 months after primary completion.
Of 41 phase 2 interventional studies under Atrial Fibrillation, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 12 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abelacimab
Anthos Therapeutics, Inc.